GLP-1 results timeline: realistic weight loss month by month

Most people considering GLP-1 therapy want to know one thing first: how much weight will I lose, and how quickly. The honest answer is that the range is wide, but the clinical evidence gives us a reasonable map of what to expect.

This is what realistic outcomes look like, based on what the trial data shows and what patients actually experience in the real world.

Setting realistic expectations

The clinical evidence is clear on average outcomes. Over 12 months, most patients on GLP-1 therapy lose between 5 and 20 percent of their starting body weight. The average lands around 12 to 15 percent. For someone starting at 100 kg, that means 12 to 15 kg gone by the one-year mark. For someone starting at 130 kg, around 16 to 20 kg.

The variation around that average is significant. About 20 percent of patients are super-responders, losing more than 20 percent of body weight. About 60 percent fall in the typical 10 to 20 percent range. The remaining 20 percent are slower responders who lose between 5 and 10 percent. Less than 5 percent of patients lose meaningful weight at all, usually due to underlying issues their doctor needs to investigate.

The pace of loss is not linear. Most of the weight comes off in the first six months, then the rate slows as the body approaches a new equilibrium. This is normal and expected, not a sign of failure.

The patients who do best are not the fastest losers. They are the ones whose loss is steady, sustainable, and paired with habits that hold up after the medication stops.

Month one

Expected loss: 2 to 5 kg.

The first month is mostly about adjustment. The dose is at the starting level, deliberately low, so the medication is exerting modest effect rather than full therapeutic effect. The weight that comes off in this window is often a mix of reduced food volume, water shifts, and the early beginnings of fat loss.

The number on the scale at week four is less important than the changes you feel. Most patients report substantially reduced appetite, less food noise, and the start of feeling more comfortable in their clothes. The scale catches up to those feelings in the months that follow.

If you have lost less than 1 kg by the end of month one, this is worth flagging with your doctor. It is sometimes normal, particularly for women near a menstrual phase or for patients with significant water retention initially. But it can also indicate that the dose needs to be adjusted or that something else clinical is going on.

Months two and three

Expected loss: 4 to 8 kg additional, totalling 6 to 13 kg from the start.

This is when the real loss begins. The dose has escalated to therapeutic levels, the body has adapted to the medication, and the calorie deficit you have been running for weeks is starting to show on the scale and in the mirror.

Most patients describe months two and three as the satisfying phase. Clothes that were tight are now loose. Weight on the scale is dropping at a visible pace, usually 0.5 to 1 kg per week for most patients. Energy levels often improve as the body adapts. People around you start noticing.

This is also when habits become important. The medication is doing the work on appetite. Whether the loss is fat or a mix of fat and muscle depends largely on whether you are getting enough protein and doing some form of resistance training. Patients who pair the medication with 1.2 to 1.6 g of protein per kg of body weight and two or three short strength sessions per week end up with much better body composition than those who simply eat less of everything.

Months four to six

Expected loss: 3 to 6 kg additional, totalling 9 to 19 kg from the start.

The pace of loss usually starts to settle in this window. Where week-by-week loss was 1 kg in months two and three, it might drop to 0.5 kg per week or slightly less. This is not a plateau, it is the body responding to a smaller frame. A 90 kg person needs fewer calories than a 100 kg person did, so the deficit naturally narrows.

By the six-month mark, most patients have lost around 10 to 18 kg from their starting weight, depending on where they started. This is enough to substantially improve weight-related health conditions, drop two or three clothing sizes, and notice meaningful changes in physical capacity. Stairs feel easier. Sleep usually improves. Blood pressure often comes down. Blood sugar normalises in patients with prediabetes.

Some patients experience a temporary slowdown around month four or five, sometimes called the first plateau. This is usually a 2 to 3 week period where the scale stops moving despite continued effort. It is almost always followed by a renewed drop. Patience is the right response, not panic.

Months seven to twelve

Expected loss: 2 to 5 kg additional, totalling 11 to 24 kg from the start.

This is the consolidation phase. Loss continues but more slowly, typically around 0.5 kg per week or less. The body has reached a new working weight and the easy losses are behind you.

This is also when many patients start thinking about maintenance. Conversations with the doctor turn to whether to continue at full dose, step down to a maintenance dose, or begin planning an exit from medication. There is no universal answer. Some patients have more weight they want to lose. Others are happy where they are and want to maintain. Some are ready to test whether their habits will hold without medication.

At the twelve-month mark, a patient who started at 95 kg might weigh 78 to 82 kg. A patient who started at 130 kg might weigh 108 to 115 kg. These are real, sustainable outcomes from a real clinical intervention. They are not the dramatic crash-diet results some marketing implies, but they are the kind of weight loss that improves health and stays gone if maintained.

Beyond the first year

The second year of GLP-1 therapy is where the question of sustainability gets answered. Patients who continue at therapeutic dose tend to maintain their loss and sometimes lose a small additional amount, usually 2 to 5 kg in year two. Patients who step down to a maintenance dose typically maintain their loss with the medication still doing some background work. Patients who stop the medication entirely are more variable, with about half maintaining most of their loss through habits, and about half regaining 30 to 50 percent of the loss over two years.

The factors that predict successful maintenance after stopping are not mysterious. Adequate protein intake, regular strength training, decent sleep, and a sustainable approach to eating. Patients who built those habits during the GLP-1 period usually keep most of the loss. Patients who treated the medication as the entire intervention often regain.

What affects your timeline

Several factors influence where you land in the range. Knowing them helps set realistic expectations for your specific situation.

Starting weight. Patients with more weight to lose generally lose more absolute kilograms, though sometimes a similar percentage. A 130 kg person losing 15 percent loses nearly 20 kg, while a 90 kg person losing 15 percent loses 13.5 kg. Both are excellent results.

Age. Younger patients tend to respond slightly faster, but the difference is smaller than people expect. Patients in their 50s and 60s respond well, particularly when they pair the treatment with strength training that protects muscle mass.

Sex. Men often lose more kilograms in absolute terms because they typically start at higher weights and have more lean muscle mass driving metabolism. Women often lose similar percentages but the visible changes can be slower because women tend to retain more weight in places that mask waist loss.

Dose. Higher therapeutic doses produce more loss on average, but also more side effects. Your doctor works with you to find the dose that produces the best loss-to-side-effect ratio for your situation.

Lifestyle alongside. This is the variable you control most. Adequate protein, some form of regular movement, decent sleep, and reasonable hydration all amplify the medication's effect. Skipping these does not stop weight loss, but it reduces the quality of the loss and the sustainability after treatment ends.

Other medications. Some medications reduce the response to GLP-1 therapy, including certain antidepressants, beta blockers, and corticosteroids. Your doctor takes these into account when planning your dose schedule.

The bottom line

Realistic GLP-1 weight loss looks like 10 to 18 percent of starting body weight over twelve months, with most of the loss in the first six months and a steadier pace after that. Some patients lose more, some lose less, and the variation is influenced by dose, lifestyle, age, sex, and starting weight.

The patients who get the best outcomes are not the ones chasing fast results. They are the ones who treat the medication as a tool that gives them a year to build sustainable habits, then carry those habits into the rest of their lives.